AstraZeneca strengthens its oncology R&D with in-licensing of CMG901 from China-based biotech KYM Biosciences

AstraZeneca strengthens its oncology R&D with in-licensing of CMG901 from China-based biotech KYM Biosciences

Submitted by admin on February 24, 2023 - 9:16am
Source: 
Medical Marketing and Media
News Tags: 
AstraZeneca
CMG901
antibody-drug conjugate
gastric cancer
KYM Biosciences
Headline: 
AstraZeneca strengthens its oncology R&D with in-licensing of CMG901 from China-based biotech KYM Biosciences
snippet: 


AstraZeneca has in-licensed CMG901, an experimental antibody drug conjugate (ADC) for treating gastric cancer, from China-based biotech KYM Biosciences, firms said Thursday.

Do Not Allow Advertisers to Use My Personal information